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Abstract
Background: Understanding the correlates of HIV shedding is important to inform strategies to reduce HIV infectiousness.
We examined correlates of genital HIV-1 RNA in women who were seropositive for both herpes simplex virus (HSV)-2 and
HIV-1 and who were enrolled in a randomised controlled trial of HSV suppressive therapy (aciclovir 400 mg b.i.d vs. placebo)
in Tanzania.
Methodology: Samples, including a cervico-vaginal lavage, were collected and tested for genital HIV-1 and HSV and
reproductive tract infections (RTIs) at randomisation and 6, 12 and 24 months follow-up. Data from all women at
randomisation and women in the placebo arm during follow-up were analysed using generalised estimating equations to
determine the correlates of cervico-vaginal HIV-1 RNA detection and load.
Principal Findings: Cervico-vaginal HIV-1 RNA was detected at 52.0% of 971 visits among 482 women, and was
independently associated with plasma viral load, presence of genital ulcers, pregnancy, bloody cervical or vaginal discharge,
abnormal vaginal discharge, cervical ectopy, Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis,a n
intermediate bacterial vaginosis score and HSV DNA detection. Similar factors were associated with genital HIV-1 RNA load.
Conclusions: RTIs were associated with increased presence and quantity of genital HIV-1 RNA in this population. These
results highlight the importance of integrating effective RTI treatment into HIV care services.
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Introduction
Plasma HIV-1 RNA viral load (PVL) is a major determinant of
HIV transmission [1] and studies report a strong correlation
between PVL and both genital HIV-1 detection and viral load.
However, genital HIV shedding is more variable than PVL and is
also influenced by local factors [2]. A recent systematic review and
meta-analysis summarised the association between genital tract
infections and genital HIV-1 [3] and reported that, in addition to
PVL, genital HIV-1 detection is associated with both symptomatic
and asymptomatic reproductive tract infections (RTIs). Treatment
studies support these findings with a reduction in genital HIV-1
RNA load following treatment for Neisseria gonorrhoeae, Chlamydia
trachomatis, Trichomonas vaginalis and Candida albicans [4,5]. Suppres-
sive therapy for herpes simplex virus type 2 (HSV-2) has been
shown to reduce both detection and quantity of genital HIV-1
RNA over periods of upto three months in several randomised
controlled trials (RCTs) [6,7,8,9,10,11]. Episodic therapy for
HSV-2 has shown less consistent results [12,13,14].
In addition to RTIs, hormonal contraceptives and pregnancy
have been associated with genital HIV-1 DNA detection
[15,16,17] and more recently, a dose-response association between
vaginal cleansing and HIV-1 RNA shedding has been reported
[18].
In this paper we report factors associated with presence and
quantity of cervico-vaginal HIV-1 RNA in HIV-infected women
working in bars, guesthouses and other recreational facilities, who
were enrolled in an individually randomised, placebo-controlled
trial of herpes suppressive therapy in Tanzania.
Materials and Methods
Following screening for HSV-2 antibodies, eligible HSV-2
seropositive women working in food or recreational facilities in 19
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in a randomised double-blind placebo-controlled trial of acyclovir
(400 mg b.i.d) (ISRCTN35385041). Study procedures, including
those for enrolment and eligibility criteria, have been described in
detail previously [19,20]. Both HIV-1 seronegative and seropos-
itive women were enrolled to examine the effect of acyclovir on
HIV acquisition and cervico-vaginal HIV-1 shedding, respectively.
There was no evidence of an impact of acyclovir 400 mg b.i.d on
either HIV acquisition or genital HIV-1 RNA shedding [20,21].
For the purposes of the study reported here, the study
population was restricted to the women who were HIV-1
seropositive at enrolment to the trial.
Ethics statement
The trial protocol was approved by the London School of
Hygiene & Tropical Medicine Ethics Committee and the Medical
Research Coordinating Committee of Tanzania. Women provid-
ed written or fingerprinted consent to participate [20,21].
Study participants and trial procedures
At enrolment, venous blood samples were taken and partici-
pants were asked about their sexual behaviour, vaginal cleansing
practices, RTI symptoms and history of symptoms consistent with
HSV-2 infection. Vaginal cleansing was defined as inserting
fingers (dry or wet) or any other substances (water, other liquids or
items like cloths) into the vagina specifically to clean the vagina.
During a genital examination, swabs were taken from the vagina
and cervix for the diagnosis of RTIs. An additional swab was taken
from any genital ulcers. Prior to the cervical swab, genital
secretions were collected by cervico-vaginal lavage (CVL) using
3 ml of phosphate-buffered saline [22]. Follow-up visits were
conducted at the study clinic every three months for 12 or 30
months depending on the woman’s date of enrolment. A clinical
examination was carried out every 6 months, and genital swabs
and a CVL were taken at 6, 12 and 24 month follow-up visits.
Women were asked to avoid vaginal cleansing within the 24 hours
before attending the clinic.
At each visit, RTIs were treated syndromically. Women were
offered treatment at their next scheduled follow-up visit for any
asymptomatic sexually transmitted infections (STIs) identified
through laboratory testing of the cervical and vaginal swabs. At
every clinic visit, all women were offered family planning,
condoms, risk reduction counselling and voluntary counselling
and testing for HIV. Antiretroviral therapy (ART) became
available in selected study communities during the trial and
HIV-positive women who had asked to know their status were
referred to these clinics for assessment and were given help with
transport where requested. Funding was provided to allow
participants to travel to their nearest care and treatment centre
for 12 to 18 months after the trial.
Laboratory analyses
Sera collected during screening and randomisation were tested
for HSV-2 and HIV-1 antibodies by ELISA as described
previously [20]. Randomisation sera were tested for syphilis using
a quantitative rapid plasma reagin (RPR) test (Immutrep RPR,
Omega Diagnostics Ltd, Alva, UK) and the Treponema pallidum
particle agglutination assay (Serodia TPPA, Fujirebio Inc, Tokyo,
Japan). RPR positive, TPPA negative/indeterminate samples were
tested by a fluorescent treponemal antibody assay (FTA, Trepo-
Spot IF, bioMe ´rieux, Marcy l’Etoile, France). Follow-up sera were
tested by RPR. New RPR positive samples were tested by TPPA
and FTA if appropriate.
Vaginal and cervical swabs were tested for other RTIs
[19,20,23]. Heat-fixed, gram-stained vaginal smears were exam-
ined by light microscopy for evidence of bacterial vaginosis using
the Ison-Hay grading scheme [24]. Trichonomas vaginalis was
diagnosed through examination using light miscroscopy of vaginal
wet preparations and cultures (InPouch TV, BioMed Diagnostics,
San Jose, California, USA). Vaginal wet preparations were also
examined for evidence of Candida albicans hyphae and spores.
Cervical swabs were tested by polymerase chain reaction (PCR)
for Neisseria gonorrhoeae and Chlamydia trachomatis (Amplicor CT/NG
PCR assay, Roche Diagnostics, Branchburg, NJ, USA). Genital
ulcer swabs were tested for T. pallidum, HSV and Haemophilus
ducreyi by PCR.
NucliSensH miniMAG and subsequently easyMAG (bioMe ´r-
ieux) was used to extract nucleic acids from plasma and CVL
supernatants. Extractions of CVL cell pellets used the Qiagen
QIAamp DNA Blood Mini Kit (Qiagen, Courtabeouf, France).
HIV-1 RNA was quantified in CVL supernatants and plasma
by in-house Real-Time PCR as described previously [25] but
using a shorter forward primer. HSV DNA was quantified in CVL
supernatants by in-house real-time PCR [26]. Thresholds for
quantitation were 360 copies/ml for cervico-vaginal HIV-1 RNA,
300 copies/ml for cervico-vaginal HSV DNA and 300 copies/ml
for plasma HIV-1 RNA. Nucleic acids extracted from the CVL
pellet were used to detect Y-chromosome DNA (Quantifiler
TM Y
Human Male DNA Quantification kit, Applied Biosystems,
Courtaboeuf, France) as evidence for contamination with male
secretions. Quantifications were carried out using the Applied
Biosystems 7300 Real-time PCR System (Applied Biosystems).
Statistical methods
Data were double-entered and verified in Dbase IV (dataBased
Intelligence) and statistical analyses were carried out using Stata
10.0 (Stata Corporation, College Station, Texas, USA).
Factors associated with cervico-vaginal HIV-1 RNA were
examined using data from all women at randomisation and
women in the placebo arm at 6, 12 and 24 month follow-up visits.
Women in the aciclovir arm were excluded since other studies
have shown that suppressive therapy with aciclovir can reduce
plasma and genital HIV RNA levels. Data were censored when
women started ART. Separate analyses were carried out of factors
associated with (i) detection of HIV-1 RNA and (ii) HIV-1 RNA
load (log10 transformed) among those with detectable HIV-1
RNA. Factors associated with HIV-1 RNA load were only
examined in those with detectable HIV-1 RNA since there were a
large number of women with no detectable shedding and replacing
undetectable values with zero or half the limit of quantification
would have resulted in a highly skewed distribution. Logistic and
linear regression models with general estimating equations (GEE)
and an exchangeable correlation matrix were used to assess factors
associated with detection and quantity of cervico-vaginal HIV-1
RNA, respectively. PVL was hypothesised a priori to be strongly
associated with cervico-vaginal HIV-1 RNA and was adjusted for
in all analyses in order to examine local correlates of HIV
shedding. Statistical significance was assessed using the Wald test.
For both the analysis of correlates of HIV-1 RNA detection and
the analysis of correlates of HIV-1 RNA load, factors associated at
p,0.15 were included in a multivariable model and retained in
the final model if they were independently associated with the
outcome (p,0.1). RTIs were defined on the basis of laboratory
results, not syndromic diagnoses.
Further linear regression analyses of the association between
HIV-1 RNA and HSV DNA viral loads were conducted for: i) all
women with detectable HSV DNA by assigning a value of half the
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RNA (to examine the overall association between HSV and HIV
shedding, irrespective of whether HIV shedding was detected); and
ii) in women with both detectable HSV DNA and detectable HIV-
1 RNA. Results of analyses restricted to samples without visible
blood or detectable Y-chromosome, to avoid misclassification of
results by contamination with virus originating from the blood or a
male partner, are also shown.
Results
Characteristics of the study population
A flowchart of enrolment and full details of the study population
have been published previously [21]. In total, 484 dually HSV-2/
HIV-1 seropositive women were enrolled and randomised to
aciclovir (253 women) or placebo (231 women). Data were
censored when women started ART and one woman was excluded
from analysis as she was on ART at enrolment. Data were
analysed from a total of 971 visits (482 of the eligible 483 women
at enrolment and 489 of 631 (77%) eligible follow-up visits i.e. a
total of 87% of eligible visits). These 489 follow-up visits were
made by 204 women on placebo. Most missing data on booked
visits (134/143 visits; 94%) were due to women not attending the
visit. The remainder (9/143; 6%) resulted from missing outcome
or PVL data.
At enrolment, the median age of participants was 28 years,
18.6% were married or living as married and 46.1% worked as
local food handlers. The median reported age at first sex was 16
years and 38.6% of participants reported 10 or more lifetime
sexual partners. Sex in the last year during menstruation was
reported by 15.9% of women. Most women (61.4%) reported
practising vaginal cleansing more than once a day. A history of
genital ulcers was reported by 31.1% of women and 24.1%
reported an episode of genital ulceration within the last year.
Laboratory-confirmed RTIs were prevalent at baseline, espe-
cially bacterial vaginosis (BV) and T. vaginalis (70.1% and 35.5% of
women respectively), but also N. gonorrhoeae (7.1%), C. trachomatis
(6.0%) and C. albicans (10.6%). Of the 204 women attending at
least one follow-up visit, 83.3% had BV during at least one follow-
up visit, 38.2% had T. vaginalis, 11.8% had N. gonorrhoeae, 11.3%
had C. trachomatis and 17.2% had C. albicans.
Factors associated with cervico-vaginal HIV-1 RNA
detection
Cervico-vaginal HIV-1 RNA was detected at 505 visits (52.0%).
Tables 1 & 2 show the association between HIV-1 RNA detection
and behavioural and clinical factors. HIV-1 RNA detection was
not increased in those using hormonal contraceptives, and there
was no association with vaginal cleansing. As expected, prevalence
of cervico-vaginal HIV-1 RNA detection was strongly associated
Table 1. Behavioural characteristics and association with cervico-vaginal HIV-1 RNA detection (in 482 women at 971 visits) and
HIV-1 RNA load.
No. of visits
HIV-1 RNA
detected No. (%)
PVL-adjusted
OR* (95%CI)
Mean HIV RNA load
(log10 copies/ml)
PVL-adjusted regression
coefficient* (95%CI)
Currently using hormonal contraceptive
P=0.08 P=0.41
No 514 268 (52.1) 1 3.64 -
Yes 436 224 (51.4) 1.03 (0.76, 1.38) 3.65 0.05 (20.07, 0.18)
Pregnant 21 13 (61.9) 2.91 (1.15, 7.37) 3.48 20.13 (20.47, 0.19)
Frequency of vaginal cleansing (per/day)
{
P=0.96 P=0.02
0 324 172 (53.1) 1 3.69 -
1 51 26 (51.0) 1.00 (0.57, 1.76) 3.45 20.33 (20.63, 20.03)
2 229 122 (53.3) 0.99 (0.63, 1.55) 3.80 0.04 (20.13, 0.21)
3 291 151 (51.9) 0.90 (0.61, 1.32) 3.53 20.19 (20.35, 20.02)
$4 74 32 (43.2) 0.84 (0.45, 1.55) 3.50 20.16 (20.41, 0.10)
Time since last vaginal cleansing
P=0.49 P=0.41
.12 hours 503 262 (52.1) 1 3.60 -
7–12 hours 138 74 (53.6) 1.13 (0.74, 1.73) 3.66 0.05 (20.12, 0.22)
4–6 hours 151 74 (49.0) 0.94 (0.65, 1.37) 3.76 0.15 (20.04, 0.34)
1–3 hours 179 95 (53.1) 1.29 (0.87, 1.92) 3.64 0.08 (20.09, 0.24)
Cleansed with
P=0.46 P=0.30
No cleansing 503 262 (52.1) 1 3.60 -
Water 187 96 (51.3) 0.98 (0.67, 1.43) 3.74 0.09 (20.05, 0.26)
Soap & water 281 147 (52.3) 1.22 (0.88, 1.70) 3.64 0.09 (20.05, 0.23)
P-values for regression coefficients calculated using Wald test.
*Adjusted for PVL as a categorical variable;
{Recorded at enrolment.
doi:10.1371/journal.pone.0017480.t001
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PVL to 87.4% among those with PVL of 5.5 log10 copies/ml or
greater. After adjusting for PVL, cervico-vaginal HIV-1 RNA
detection was not associated with a history of genital ulceration but
was associated with being pregnant, presence of genital ulcers on
examination, abnormal or bloody cervical or vaginal discharge
and cervical ectopy (Tables 1 & 2). Biological factors associated
with cervico-vaginal HIV-1 RNA detection were N. gonorrhoeae, C.
trachomatis, T. vaginalis, an intermediate BV score and HSV DNA
detection (Table 3).
In the multivariable model (Table 4), HIV-1 RNA detection
was independently associated with pregnancy, the presence of
Table 2. Behavioural characteristics and association with cervico-vaginal HIV-1 RNA detection (in 482 women at 971 visits) and
HIV-1 RNA load.
No. of visits
HIV-1 RNA
detected No. (%) PVL-adjusted OR* (95%CI)
Mean HIV RNA load
(log10 copies/ml)
PVL-adjusted regression
coefficient* (95%CI)
Self reported frequency of ulcers
{
P=0.30 P=0.83
No history of ulcers 677 330 (48.7) 1 3.62 -
Only once/twice ever 77 40 (52.0) 0.83 (0.50, 1.38) 3.75 0.07 (20.15, 0.30)
Once/twice per year 67 39 (58.2) 1.22 (0.60, 2.46) 3.78 0.07 (20.20, 0.34)
Every 3 months 67 47 (70.2) 1.69 (0.97, 2.93) 3.56 20.09 (20.31, 0.13)
Monthly 76 45 (59.2) 1.26 (0.64, 2.49) 3.67 20.01 (20.26, 0.23)
Self reported episode of GUD in last year
{
P=0.35 P=0.66
No 733 362 (49.4) 1 3.64 -
Yes 233 140 (60.1) 1.19 (0.82, 1.72) 3.65 20.03 (20.17, 0.11)
Genital ulcers on examination
P=0.05 P=0.57
No 940 482 (51.3) 1 3.64 -
Yes 31
{ 23 (74.2) 2.23 (0.99, 5.02) 3.72 20.06 (20.26, 0.14)
Blisters on examination
P=0.56 P=0.49
No 958 495 (51.7) 1 3.64 -
Yes 13 10 (76.9) 1.43 (0.44, 4.63) 3.74 20.17 (20.65, 0.31)
Cervical discharge
P=0.0002 P=0.002
None/Normal 656 317 (48.3) 1 3.59 -
Present
1 176 101 (57.4) 1.33 (0.93, 1.91) 3.65 0.03 (20.13, 0.18)
Bloody 139 87 (62.6) 2.48 (1.59, 3.84) 3.81 0.25 (0.11, 0.38)
Vaginal discharge
P,0.0001 P=0.002
Normal 477 205 (43.0) 1 3.56 -
Abnormal
I 355 208 (58.6) 1.90 (1.39, 2.59) 3.65 0.12 (20.02, 0.25)
Bloody 139 92 (66.2) 3.74 (2.38, 5.88) 3.81 0.29 (0.15, 0.43)
PID diagnosis
P=0.27 P=0.32
No 866 440 (50.8) 1 3.62 -
Yes 105 65 (61.9) 1.30 (0.81, 2.09) 3.76 0.10 (20.09, 0.29)
Cervical ectopy
P=0.02 P=0.13
No 865 437 (50.5) 1 3.61 -
Yes 106 68 (64.2) 1.72 (1.07, 2.75) 3.81 0.16 (20.05, 0.37)
P-values for regression coefficients calculated using Wald test.
*Adjusted for PVL as a categorical variable;
{Recorded at enrolment;
{Of 30 ulcer swabs taken 19 (63%) had no aetiology, 10 (33%) were HSV-2 and 1 (3%) was syphilis;
1White, cream or purulent or malodorous;
ICurdlike, white or purulent.
doi:10.1371/journal.pone.0017480.t002
Correlates of Genital HIV Shedding
PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17480genital ulcers, bloody cervical discharge, cervical ectopy, RTIs (N.
gonorrhoeae, C. trachomatis, T. vaginalis, an intermediate BV score) and
HSV DNA detection (adjusted odds ratio (aOR)=1.55, 95%CI
0.99–2.42). A PVL of 5.5 log copies/ml was associated with 15.57
times increased odds of HIV-1 RNA detection compared with a
PVL of 2.45–4.0 log copies/ml. Vaginal discharge was excluded
due to collinearity with cervical discharge but associations were
similar in a model including vaginal discharge instead of cervical
Table 3. Biological characteristics and association with cervico-vaginal HIV-1 RNA detection (in 482 women at 971 visits) and HIV-1
RNA load.
No. of visits
HIV-1 RNA
detected No. (%) PVL-adjusted OR* (95%CI)
Mean HIV RNA load
(log10 copies/ml)
PVL-adjusted regression
coefficient* (95%CI)
N gonorrhoeae
P=0.02 P=0.05
No 911 467 (51.3) 1 3.62 -
Yes 59 38 (64.4) 2.02 (1.13, 3.59) 3.84 0.25 (20.00, 0.51)
C trachomatis
P=0.05 P=0.73
No 915 469 (51.3) 1 3.64 -
Yes 54 36 (66.7) 1.99 (0.99, 3.99) 3.66 0.04 (20.17, 0.24)
T. vaginalis
P=0.008 P=0.01
No 696 340 (48.9) 1 3.60 -
Yes 273 164 (60.1) 1.56 (1.12, 2.17) 3.72 0.16 (0.03, 0.29)
C. albicans
P=0.79 P=0.57
No 878 453 (51.6) 1 3.64 2
Yes 91 51 (56.0) 1.07 (0.65, 1.77) 3.63 20.05 (20.24, 0.13)
Bacterial vaginosis
P=0.01 P=0.003
Normal 113 59 (52.2) 1 3.45 -
Intermediate 192 121 (63.0) 1.69 (1.01, 2.83) 3.73 0.31 (0.15, 0.48)
BV 626 306 (48.9) 0.89 (0.58, 1.38) 3.64 0.21 (0.06, 0.35)
Slides unclassifiable 40 19 (47.5) 0.91 (0.44, 1.88) 3.68 0.20 (20.09, 0.50)
High-titre active syphilis
{
P=0.21 P=0.56
No/past infection 927 480 (51.8) 1 3.65 -
Yes 44 25 (56.8) 1.53 (0.79, 2.98) 3.55 20.08 (20.37, 0.20)
Y-PCR positive
P=0.12 P=0.02
No 753 407 (54.1) 1 3.68 -
Yes 209 95 (45.5) 0.76 (0.54, 1.08) 3.48 20.17 (20.32, 20.03)
HSV DNA detected
P=0.04 P=0.84
No 842 419 (49.8) 1 3.62 -
Yes 129 86 (66.7) 1.58 (1.03, 2.41) 3.72 20.02 (20.18, 0.15)
PVL (log copies/ml)
P,0.0001 P,0.0001
Undetectable 92 6 (6.5) 0.22 (0.10, 0.51) 3.83 0.55 (20.17, 1.26)
2.45–4.0 215 62 (28.8) 1 3.18 -
4.0–,5.0 345 183 (53.0) 2.65 (1.79, 3.92) 3.46 0.26 (0.11, 0.41)
5.0–,5.5 192 143 (74.5) 6.19 (3.98, 9.64) 3.77 0.56 (0.39, 0.74)
$5.5 127 111 (87.4) 15.30 (8.38, 27.92) 4.02 0.83 (0.63, 1.03)
P-values for regression coefficients calculated using Wald test.
*Adjusted for PVL as a categorical variable;
{new RPR positive with titre $8 & TPPA/FTA positive or RPR positive with titre $8 and previously RPR positive.
doi:10.1371/journal.pone.0017480.t003
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bloody (aOR=3.80, 95%CI 2.37–6.10) vaginal discharge were
associated with increased odds of HIV-1 RNA detection (results
not shown).
Correlates of cervico-vaginal HIV-1 RNA load
The correlates of cervico-vaginal HIV-1 RNA load were
examined in the 505 visits with detectable HIV-1 RNA. The
quantity of cervico-vaginal HIV-1 RNA detected ranged from
2.55 to 6.58 log copies/ml. There was little association between
behavioural variables and HIV-1 RNA load (Table 1). Among
those with detectable HIV-1 RNA, genital viral load was
associated (p,0.15) with vaginal cleansing, having either bloody
cervical or vaginal discharge, cervical ectopy, N. gonorrhoeae, T.
vaginalis, an intermediate BV grading and BV (Tables 2 & 3).
There was no association with C. trachomatis or HSV DNA
detection. Presence of Y-chromosome was associated with a
reduced HIV-1 RNA load. With the exception of cervical ectopy,
these factors were independently associated with HIV-1 RNA load
in multivariate analysis (Table 5). Coefficients were similar when
vaginal discharge was included instead of cervical discharge
(results not shown).
Relationship between HIV-1 RNA and HSV DNA
Cervico-vaginal HSV DNA was detected at 129 visits (13.3%).
The quantity of cervico-vaginal HSV DNA detected ranged from
2.49 to 6.97 log copies/ml. After adjusting for PVL, there was
weak evidence for an association between HIV-1 RNA and HSV
DNA viral loads at all visits when HSV was shed (Figure 1) when
undetectable HIV-1 RNA was assigned a value of half the
threshold of quantification (N=129; adjusted regression coeffi-
cient =0.11, 95%CI 20.00, 0.22) and when restricted to samples
without blood or Y-chromosome (N=93; adjusted regression
coefficient=0.15, 95%CI 0.02, 0.27). Among the 86 samples with
both cervico-vaginal HIV-1 RNA and HSV DNA detected, there
was also weak evidence for an association (adjusted regression
coefficient=0.10, 95%CI 20.01, 0.22) and when restricted to
samples without visible blood or Y-chromosome detected (N=62;
adjusted regression coefficient=0.11, 95%CI 20.03, 0.24).
Similar results were seen in both the analysis unadjusted for
PVL and when women with genital ulcers were excluded.
Discussion
In this study we examined correlates of genital HIV-1 RNA
detection and viral load in a cohort of HSV-2 seropositive
Tanzanian female facility workers enrolled in an HSV suppressive
therapy trial. Genital HIV-1 RNA detection and viral load were
associated with several clinical and biological factors in this cohort
but there were no significant associations with behavioural
variables measured in this study.
These findings are broadly consistent with other studies
reporting an association between RTIs and genital HIV-1 RNA
detection and viral load, especially with infections affecting the
cervix [27,28,29,30]. A meta-analysis reported significant associ-
ations between HIV-1 RNA detection and N. gonorrhoeae, C.
trachomatis, vaginal discharge, cervical discharge and candidiasis
and a non-significant association for both HSV DNA detection
and genital ulcers [3]. Treatment studies support elevated viral
loads with co-infection with N. gonorrhoeae, C. trachomatis, T. vaginalis
and C. albicans [4,5] and a reduction in viral load following
treatment.
This study population was not selected based on genital
symptoms or signs, but the high prevalence of RTIs and the
association that was found between several RTIs and HIV
shedding, although modest for some RTIs, highlights the potential
for effective STI management to reduce HIV infectiousness by
reducing HIV load in such populations. This is supported by
observational data and one community randomised trial of STI
treatment which reported 40% lower HIV incidence in commu-
nities that received improved syndromic management of STIs
[31]. Other cluster trials of RTI treatment have produced
apparently inconsistent results [32,33,34] and extensive work has
been carried out to explore the reasons for these inconsistencies
[35,36,37]. Although the association between HSV and HIV
shedding in our study was weak, suppressive HSV therapy has
been demonstrated to reduce HIV shedding [6,7,8,9,10,11] even
among women who had detectable shedding while on antiretro-
virals [38], highlighting the importance of considering the impact
of other local co-factors on HIV infectiousness. However, this
impact of HSV suppressive therapy did not translate into an effect
on HIV transmission in a recent study among HIV discordant
couples despite a 0.25 log10 reduction in PVL [39]. The authors
suggest that the reduction in genital HIV may have been
insufficient to impact HIV transmission. More research is needed
to understand the relationship between HIV shedding and
transmission and, most importantly, what decrease in genital
HIV would translate into a population level impact on HIV
transmission. These are important questions for trials which will
examine the impact of early initiation of antiretroviral therapy on
population HIV acquisition.
Cervical and abnormal, vaginal discharge were associated with
genital HIV in this analysis. Maintaining services that can provide
good syndromic RTI management remains important, especially
where laboratory diagnosis of RTIs is not readily available.
Increased integration of RTI services into HIV care settings may
be beneficial in widening service access to populations who may
less readily engage with services.
In contrast to results of a recent meta-analysis [3], we observed
a strong association between T. vaginalis and HIV-1 RNA
detection. Although this may have arisen by chance, the moderate
point estimate in our study suggests that the association may not be
strong enough to have been detected in studies with a small sample
size or low prevalence of T. vaginalis. Additionally, in our study,
genital HIV-1 RNA detection was found to be associated with an
intermediate BV score, but not with BV. Data from other studies
are inconclusive [28,40,41] but in vitro studies have demonstrated
that certain bacteria associated with BV induce HIV expression or
activate the HIV long terminal repeat [42,43] but further studies
are needed to elucidate the association between BV and genital
HIV shedding.
We found significantly increased odds of HIV-1 RNA detection
with HSV DNA detection and genital ulceration. In the meta-
analysis [3], both these estimates showed significant inter-study
heterogeneity. Our findings and a study reporting a four-fold
increase in HIV transmission probabilities with genital ulceration
[44] highlight the potential importance of HSV treatment in HIV
positive individuals, especially those who are immuno-compro-
mised and who may have more frequent and more prolonged
HSV recurrences [45]. Recent trials estimating the effect of
episodic HSV therapy on genital HIV-1 shedding, however, have
reported little effect [12,13,14]. Furthermore, the multi-country
discordant couples study also found no reduction in HIV
transmission with HSV suppressive therapy despite a 73%
reduction in genital ulcers due to HSV-2 [39].
We did not find an association between HIV-1 RNA detection
and hormonal contraceptive use, although this has been more
frequently associated with HIV-infected cells [16,17]. However,
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No. of visits
HIV-1 RNA
detected No. (%) Adjusted OR (95%CI)*
Currently using hormonal contraceptive
P=0.07
No 512 268 (52.3) 1
Yes 434 223 (51.4) 1.07 (0.79, 1.46)
Pregnant 21 13 (61.9) 3.17 (1.19, 8.46)
Genital ulcers on examination
P=0.10
No 936 481 (51.4) 1
Yes 31 23 (74.2) 2.01 (0.88, 4.60)
Cervical discharge
P=0.0002
None/Normal 653 316 (48.4) 1
Present
{ 175 101 (57.7) 1.22 (0.83, 1.80)
Bloody 139 87 (62.6) 2.59 (1.63, 4.12)
Cervical ectopy
P=0.04
No 861 436 (50.6) 1
Yes 106 68 (64.2) 1.68 (1.02, 2.76)
N gonorrhoeae
P=0.07
No 908 466 (51.3) 1
Yes 59 38 (64.4) 1.80 (0.96, 3.39)
C trachomatis
P=0.08
No 913 468 (51.3) 1
Yes 54 36 (66.7) 1.90 (0.92, 3.95)
T. vaginalis
P=0.01
No 695 340 (48.9) 1
Yes 272 164 (60.3) 1.58 (1.11, 2.25)
Bacterial vaginosis
P=0.03
Normal 113 59 (52.2) 1
Intermediate 191 121 (63.4) 1.39 (0.83, 2.34)
BV 623 305 (49.0) 0.75 (0.47, 1.19)
Unclassifiable 40 19 (47.5) 0.75 (0.45, 1.58)
HSV DNA detected
P=0.06
No 839 419 (49.9) 1
Yes 128 85 (66.4) 1.55 (0.99, 2.42)
PVL (log copies/ml)
P,0.0001
Undetectable 92 6 (6.5) 0.20 (0.08, 0.50)
2.45–4.0 213 62 (29.1) 1
4.0–,5.0 344 183 (53.2) 2.98 (1.98, 4.48)
5.0–,5.5 191 142 (74.4) 6.83 (4.27, 10.93)
$5.5 1270 111 (87.4) 15.57 (8.47, 28.61)
*Adjusted for hormonal contraceptive use, ulcers, cervical discharge, cervical ectopy, N. gonorrhoeae, C. trachomatis, T. vaginalis, BV, HSV shedding and PVL;
{White, cream or purulent.
doi:10.1371/journal.pone.0017480.t004
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1 RNA detection. Previous studies have found pregnancy to be
associated with increased HIV-1 DNA detection [15,46]. This
association may be explained by hormonal or cervical changes but
may also have been a chance finding.
Strengths of our study include the fact that we used CVLs to
collect genital secretions so we were able to examine simulta-
neously the association between both cervical and vaginal
infections and HIV shedding. The longitudinal design with
repeated visits allowed a high powered analysis of correlates of
HIV-1 shedding in this population. This is also a non-clinic
population enabling examination of the importance of RTIs for
HIV shedding in those not presenting to services. Unfortunately
due to small sample sizes, we were unable to examine, for each
RTI separately, whether HIV shedding was higher during
symptomatic vs. asymptomatic infections, and therefore investigate
Table 5. Factors independently associated with cervico-vaginal HIV-1 RNA load (in 311 women with detectable shedding at 499
visits).
No. of visits
Mean HIV RNA load (95%CI)
(log10 copies/ml)
Adjusted regression
coefficient
{ (95%CI)
Frequency of vaginal cleansing (per/day)
P=0.02
0 171 3.69 (3.57, 3.80) -
1 26 3.45 (3.12, 3.79) 20.34 (20.63, 20.06)
2 121 3.79 (3.67, 3.91) 0.01 (20.16, 0.19)
3 149 3.53 (3.41, 3.65) 20.18 (20.35, 20.01)
$4 32 3.50 (3.26, 3.74) 20.18 (20.43, 0.06)
Cervical discharge
P=0.003
None/Normal 311 3.59 (3.51, 3.67) -
Present { 101 3.65 (3.50, 3.81) 20.01 (20.16, 0.13)
Bloody 87 3.81 (3.65, 3.97) 0.23 (0.09, 0.37)
N gonorrhoeae
P=0.05
No 461 3.62 (3.56, 3.69) -
Yes 38 3.84 (3.55, 4.13) 0.25 (20.00, 0.51)
T. vaginalis
P=0.007
No 336 3.60 (3.53, 3.68) -
Yes 163 3.72 (3.60, 3.84) 0.17 (0.05, 0.30)
Bacterial vaginosis
P=0.02
Normal 58 3.45 (3.30, 3.61) -
Intermediate 120 3.73 (3.59, 3.86) 0.24 (0.08, 0.39)
BV 302 3.64 (3.55, 3.72) 0.12 (20.02, 0.26)
Unclassifiable 19 3.68 (3.31, 4.05) 0.05 (20.25, 0.36)
Y-PCR positive
P=0.10
No 404 3.68 (3.61, 3.75) -
Yes 95 3.48 (3.32, 3.63) 20.12 (20.26, 0.02)
PVL (log copies/ml)
P,0.0001
Undetectable 6 3.83 (2.69, 4.97) 0.66 (20.00, 1.33)
2.45–4.0 62 3.18 (3.06, 3.31) -
4.0–,5.0 180 3.45 (3.36, 3.54) 0.31 (0.16, 0.47)
5.0–,5.5 141 3.77 (3.65, 3.89) 0.61 (0.43, 0.79)
$5.5 110 4.03 (3.88, 4.18) 0.88 (0.68, 1.07)
P values calculated using Wald test.
*Adjusted for all variables in the table.
{White, cream or purulent.
doi:10.1371/journal.pone.0017480.t005
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concentrations are more likely to be increased with symptomatic
infections, these may have a greater effect on HIV shedding.
Our study confirms previous data on the importance of RTIs as
a local correlate of HIV shedding, even in a non-clinic population.
This highlights the importance of RTI treatment in HIV infected
individuals. This may be especially important in populations with
high prevalence of bacterial RTIs who are often those least able to
access adequate treatment services. Increased integration of STI
services into HIV care settings may also be beneficial. Further
research is needed to understand the relationship between HIV
shedding and HIV transmission.
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